Literature DB >> 8861652

Two-step chromatographic purification of human plasma alpha(1)-acid glycoprotein: its application to the purification of rare phenotype samples of the protein and their study by chromatography on immobilized metal chelate affinity adsorbent.

F Herve1, M C Millot, C B Eap, J C Duche, J P Tillement.   

Abstract

Alpha1-Acid glycoprotein (AAG) or orosomucoid was purified to homogeneity from human plasma by a separate two-step method using chromatography on immobilized Cibacron Blue F3G-A to cross-linked agarose and chromatography on hydroxyapatite. The conditions for the pre-purification of AAG by chromatography on immobilized Cibacron Blue F3G-A were first optimized using different buffer systems with different pH values. The overall yield of the combined techniques was 80% and ca. 12 mg of AAG were purified from an initial total amount of ca. 15 mg in a ca. 40 ml sample of human plasma. This method was applied to the purification of AAG samples corresponding to the three main phenotypes of the protein (FI*S/A, F1/A and S/A), from individual human plasma previously phenotyped for AAG. A study by isoelectric focusing with carrier ampholytes showed that the microheterogeneity of the purified F1*S/A, F1/A and S/A AAG samples was similar to that of AAG in the corresponding plasma, thus suggesting that no apparent desialylation of the glycoprotein occurred during the purification steps. This method was also applied to the purification of AAG samples corresponding to rare phenotypes of the protein (F1/A*AD, S/A*X0 and F1/A*C1) and the interactions of these variants with immobilized copper(II) ions were then studied at pH 7, by chromatography on an iminodiacetate Sepharose-Cu(II) gel. It was found that the different variants encoded by the first of the two genes coding for AAG in humans (i.e. the F1 and S variants) interacted non-specifically with the immobilized ligand, whereas those encoded by the second gene of AAG (i.e. the A, AD, X0 and C1 variants) strongly bound to immobilized Cu(II) ions. These results suggested that chromatography on an immobilized affinity Cu(II) adsorbent could be helpful to distinguish between the respective products of the two highly polymorphic genes which code for human AAG.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8861652     DOI: 10.1016/0378-4347(95)00366-5

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Appl        ISSN: 1572-6495


  5 in total

1.  Role of biantennary glycans and genetic variants of human alpha1-acid glycoprotein in enantioselective binding of basic drugs as studied by high performance frontal analysis/capillary electrophoresis.

Authors:  Y Kuroda; Y Kita; A Shibukawa; T Nakagawa
Journal:  Pharm Res       Date:  2001-03       Impact factor: 4.200

2.  Biantennary glycans as well as genetic variants of alpha1-acid glycoprotein control the enantioselectivity and binding affinity of oxybutynin.

Authors:  Tomoko Kimura; Akimasa Shibukawa; Katsumi Matsuzaki
Journal:  Pharm Res       Date:  2006-05-02       Impact factor: 4.200

3.  Comparison of methods for the purification of alpha-1 acid glycoprotein from human plasma.

Authors:  Teresa R McCurdy; Varsha Bhakta; Louise J Eltringham-Smith; Sharon Gataiance; Alison E Fox-Robichaud; William P Sheffield
Journal:  J Biomed Biotechnol       Date:  2011-03-08

4.  In vivo clearance of alpha-1 acid glycoprotein is influenced by the extent of its N-linked glycosylation and by its interaction with the vessel wall.

Authors:  Teresa R McCurdy; Varsha Bhakta; Louise J Eltringham-Smith; Sharon Gataiance; Alison E Fox-Robichaud; William P Sheffield
Journal:  J Biomed Biotechnol       Date:  2012-04-01

5.  Development of a novel system for mass spectrometric analysis of cancer-associated fucosylation in plasma α1-acid glycoprotein.

Authors:  Takayuki Asao; Shin Yazawa; Toyo Nishimura; Takashi Hayashi; Hideyuki Shimaoka; Abby R Saniabadi; Hiroyuki Kuwano
Journal:  Biomed Res Int       Date:  2013-02-13       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.